Revenue Above Guidance and Sequential Growth
Q1 total revenue of $27.9 million, which came in above the midpoint of guidance and grew 4% sequentially.
Orasure Technologies
· OSUR
May 6th, 2026
Summary
- Earnings Call Date:
- 2026-05-06
- Change Since:
- +44.67%
- Next Earnings Date:
- 2026-08-11
Earnings Call Sentiment
NeutralThe call presented a balanced picture: positive execution on cost and manufacturing initiatives led to gross margin expansion and sequential diagnostics growth, a strong cash position and ongoing buybacks support financial flexibility, and two FDA-submitted products plus near-shoring progress are meaningful near- to mid-term growth catalysts. Offsetting these positives are substantial operating losses, negative operating cash flow, elevated near-term operating expenses (including nonrecurring charges), muted demand in some Sample Management end markets due to slow NIH funding, and execution/timing risks associated with product ramps and near-shoring monetization. Given the mix of encouraging operational progress and clear near-term financial and execution risks, the overall tone is balanced.
Company Guidance
For Q2 2026 OraSure guided revenue of $27.0–$30.0 million (with a negligible amount from COVID‑19 testing) and said Q2 gross margin should be similar to Q1 (Q1 GAAP gross margin 42.3%, non‑GAAP 43.4%), with operating expense in the high‑$20 million range (excluding stock compensation) and expected to decline to the mid‑$20 million range in Q3; R&D is expected to taper in Q2–Q3, G&A to normalize beginning in Q3, and management anticipates mid‑year FDA clearances with product revenue ramping in H2 2026 and a return to breakeven operating cash flow in 2027 (Q1 operating cash flow was negative $14.0M). For context, Q1 revenue was $27.9M (+4% sequential), Diagnostics $16.9M (+12% seq) and Sample Management $9.1M (flat), Q1 GAAP operating loss was $23.3M (non‑GAAP loss $19.0M), cash and cash equivalents were $177M with zero debt, and the company repurchased $5M (1.8M shares) in Q1 and $20M (7.1M shares) over the last four quarters.
Diagnostics Segment Strength
Diagnostics revenue of $16.9 million in Q1, with an approximately even split between U.S. and international sales and sequential growth of 12%.
Gross Margin Expansion
GAAP gross margin improved to 42.3% (from 41.1% in Q1 2025, +1.2 percentage points) and non-GAAP gross margin rose to 43.4% (from 41.7% in Q1 2025, +1.7 percentage points), driven by in-sourcing production and manufacturing efficiencies.
Strong Balance Sheet and Capital Returns
Ended the quarter with $177 million in cash and cash equivalents, zero debt, and continued share repurchases (deployed $5 million in Q1 for 1.8 million shares and $20 million repurchased over the last four quarters).
Near-Term Product Catalysts
Two FDA submissions in active review with anticipated midyear clearances: an OTC rapid molecular self-test for CT/NG on the Sherlock platform and the Colli-Pee at-home urine collection device. Management expects revenue from these launches to ramp in the second half of 2026.
International Near-Shoring and Market Expansion
Delivered initial orders to a near-shoring partner in Africa during Q1, expect additional initial orders from other partners in H2 2026, and are integrating BioMedomics and expanding SickleSCAN into new national health program markets—management referred to potential opportunity sizes in the 'millions.'
Focused R&D Investment with Planned Taper
R&D investment increased to $13.7 million in Q1 due to launch and production readiness activities for CT/NG and Colli-Pee, with management expecting R&D expense to taper in Q2 and Q3 as launch preparations conclude.
Operator
Good day, and thank you for standing by. Welcome to the OraSure Technologies, Inc. 2026 First Quarter Earnings Conference Call. [Operator Instructions] Be advised that today's conference call is being recorded. I would now like to hand the conference over to your first speaker today, Jason Plagman, Vice President of Investor Relations. Please go ahead.
Jason Plagman
Good afternoon, and welcome to OraSure Technologies' First Quarter 2026 Earnings Call. Participating in the call today for OTI are Carrie Eglinton Manner, our President and Chief Executive Officer; and Ken McGrath, our Chief Financial Officer. As a reminder, today's webcast is being recorded and the recording can be found on our Investor Relations website. Before we begin, you should know that this call may contain certain forward-looking statements, including statements with respect to revenues, expenses, profitability, earnings or loss per share, and other financial performance, product development, performance, shipments and markets, business plans, regulatory filings and approvals, expectations, and strategies. Actual results could be significantly different. Factors that could affect results are discussed more fully in OTI's SEC filings, its annual report on Form 10-K for the year ended December 31, 2025, its quarterly reports on Form 10-Q, and its other SEC filings. Although forward-looking statements help to provide more complete information about future prospects, listeners should keep in mind that forward-looking statements are based solely on information available to management as of today. OTI undertakes no obligat...
Subscribe to unlock transcripts
Get The Fly Pro 7 days for free